

Date: February 05, 2026

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject:** Outcome of the Board Meeting held on Thursday, February 05, 2026

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (*formerly known as Anthem Biosciences Private Limited*) ("Company") at their meeting held on Thursday, February 05, 2026 which commenced at 11:40 a.m. and concluded at 12.55 p.m. have inter-alia, approved the following matters:

### **1. Unaudited Financial Results**

The Board of Directors (*Board*) have approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter and nine months ended December 31, 2025. The said financials results for the quarter and nine months ended December 31, 2025 were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board.

A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations.

### **2. Allotment of Equity Shares pursuant to Anthem Employee Stock Option Plan 2024**

The Board have approved allotment of 1,03,800 Equity Shares of face value of Rs. 2 (Rupees two only) each to the eligible employees of the Company upon exercise of the Options vested with them under the Anthem Employee Stock Option Plan 2024.

Consequent to this allotment, the paid-up equity share capital of the Company stand increased from Rs. 1,12,32,20,102/- (consisting of 56,16,10,051 equity shares of face value of Rs. 2 each) to Rs. 1,12,34,27,702/- (consisting of 56,17,13,851 equity shares of face value of Rs. 2 each).

The details as required under the Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are as follows:

<b>Sl No</b>	<b>Particulars</b>	<b>Disclosure - ESOP 2024</b>
1	Company Name and Address of Registered Office	<i>Anthem Biosciences Limited No. 49, F1 &amp; F2, Canara Bank Road, Bommasandra Industrial Area, Phase I, Bangalore, Karnataka, India, 560099</i>
2	Name of the Stock Exchanges on which the Company's shares are listed	<i>BSE Limited (BSE) National Stock Exchange of India Limited (NSE)</i>
3	Filing date of the statement referred in regulation 10(b) of the SEBI (SBEB) Regulations, with Stock Exchange	<i>November 03, 2025</i>
4	Filing Number, if any	<i>BSE: DCS/ESOP/IP/RG/3935/2025-26 NSE: NSE/LIST/51770</i>
5	Title of the Scheme pursuant to which shares are issued	<i>Anthem Employee Stock Option Plan 2024</i>
6	Kind of security to be listed	<i>Equity Shares</i>
7	Par value of the shares	<i>Rs. 2/-</i>
8	Number of shares issued	<i>1,03,800</i>
9	Share Certificate No., if applicable	<i>Not Applicable</i>
10	Distinctive number of the shares, if applicable	<i>573019752 - 573123551</i>
11	ISIN Number of the shares if issued in Demat	<i>INE0CZ201020</i>
12	Exercise price per share	<i>Rs. 100.75</i>
13	Premium per share	<i>Rs. 98.75</i>
14	Total Issued shares after this issue	<i>56,17,13,851</i>

15	Total Issued share capital after this issue	<i>Rs. 1,12,34,27,702</i>
16	Details of any lock-in on the shares	<i>Not Applicable</i>
17	Date of expiry of lock-in	<i>Not Applicable</i>
18	Whether shares identical in all respects to existing shares if not, when will they become identical?	<i>All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company.</i>
19	Details of listing fees, if payable	<i>Not Applicable</i>

The above intimation is also available on the Company's website at <https://www.anthembio.com/investors/>

We request you to kindly take the same on record.

Thanking you,  
 Yours truly,  
 For Anthem Biosciences Limited  
*(Formerly known as Anthem Biosciences Private Limited)*

**DIVYA**   
**PRASAD** Digital signature  
by DIVYA PRASAD  
Date: 2026.02.05  
13:07:22 +05'30'

**Divya Prasad**  
**Company Secretary & Compliance Officer**  
**Membership No: A41438**

**Independent Auditor's Review Report on the quarterly and year to date Unaudited Standalone Financial results of Anthem Biosciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review report to**  
**The Board of Directors of**  
**Anthem Biosciences Limited**  
**Bangalore**

1. We have reviewed the Unaudited Standalone Financial result of **Anthem Biosciences Limited** (the "Company"), included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter and nine months ended December 31, 2025 (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).
2. The Company's management is responsible for the preparation of the Statement, in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For K. P. Rao & Co.,**  
Chartered Accountants  
FRN: 003135S

**Raghothama Mohan Lavi**  
Digitally signed by  
Raghothama Mohan Lavi  
Date: 2026.02.05 12:58:46  
+05'30'

**Mohan R Lavi**  
Partner  
Membership No. 029340

**Place: Bangalore**  
**Date: 5<sup>th</sup> February 2026**

**UDIN: 26029340MQGTDT9002**

**ANTHEM BIOSCIENCES LIMITED**  
**CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703**  
 REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099.  
 KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND PERIOD ENDED DECEMBER 31, 2025**

Particulars						Rs in Mn
	Quarter ended		Year to date		Year End	
	31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
	Unaudited	Unaudited	Unaudited (Note 4)	Unaudited	Unaudited (Note 6)	Audited
<b>Income:</b>						
Revenue from operations	4,165.75	5,522.26	4,982.62	15,068.12	13,616.65	18,406.49
Other income	399.22	537.99	243.35	1,214.50	716.21	1,094.40
<b>Total income</b>	<b>4,564.98</b>	<b>6,060.25</b>	<b>5,225.97</b>	<b>16,282.61</b>	<b>14,332.86</b>	<b>19,500.89</b>
<b>Expenses:</b>						
Cost of materials consumed	1,805.71	2,037.12	2,545.73	5,466.78	6,458.11	8,280.79
Changes in inventories of finished goods, work-in-progress and stock in trade	(423.33)	220.98	(224.21)	484.37	(799.87)	(867.05)
Employee benefit expenses	654.71	631.58	546.51	1,971.99	1,957.42	2,521.67
Finance cost	11.27	22.32	17.86	49.65	69.86	90.89
Depreciation and amortisation expense	267.48	239.20	195.02	732.81	569.48	779.37
Other expenses	498.20	376.03	446.02	1,303.68	1,092.01	1,580.97
<b>Total expenses</b>	<b>2,814.04</b>	<b>3,527.23</b>	<b>3,526.92</b>	<b>10,009.28</b>	<b>9,347.01</b>	<b>12,386.66</b>
<b>Profit before exceptional items and tax</b>	<b>1,750.94</b>	<b>2,533.02</b>	<b>1,699.05</b>	<b>6,273.33</b>	<b>4,985.85</b>	<b>7,114.23</b>
Exceptional items (Note 7)	249.84	-	-	249.84	-	-
<b>Profit before tax</b>	<b>1,501.10</b>	<b>2,533.02</b>	<b>1,699.05</b>	<b>6,023.49</b>	<b>4,985.85</b>	<b>7,114.23</b>
<b>Tax expense</b>						
Current tax	377.80	637.51	427.62	1,515.99	1,254.84	1,820.27
Deferred tax	2.05	(88.83)	(8.49)	(81.49)	(105.24)	232.08
<b>Total tax expenses</b>	<b>379.84</b>	<b>548.68</b>	<b>419.12</b>	<b>1,434.51</b>	<b>1,149.60</b>	<b>2,052.36</b>
<b>Profit for the Period/Year</b>	<b>1,121.25</b>	<b>1,984.34</b>	<b>1,279.93</b>	<b>4,588.98</b>	<b>3,836.25</b>	<b>5,061.88</b>
<b>Other comprehensive income</b>						
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	(9.80)	(19.39)	(2.33)	(9.11)	(7.36)	(5.30)
Income tax on above	2.47	4.88	0.59	2.29	1.85	1.33
<b>Other comprehensive income/(loss) for the period/year</b>	<b>(7.33)</b>	<b>(14.51)</b>	<b>(1.74)</b>	<b>(6.82)</b>	<b>(5.50)</b>	<b>(3.96)</b>
<b>Total comprehensive income for the period/year</b>	<b>1,113.92</b>	<b>1,969.83</b>	<b>1,278.19</b>	<b>4,582.17</b>	<b>3,830.74</b>	<b>5,057.91</b>
<b>Paid-up equity share capital (face value of Rs.2 each)</b>	<b>1,123.22</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,118.15</b>
<b>Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'</b>						<b>23,613.97</b>
<b>Earnings per share (not annualised)</b>						
Basic	2.00	3.54	2.29	8.18	6.86	9.05
Diluted	1.98	3.50	2.28	8.09	6.83	9.01

See accompanying notes to financial results



**Notes to Standalone Financial Statements**

These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

2 The above statement of unaudited standalone financial results ("the Statements") of the Company for the quarter ended and period ended 31st December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 5, 2026. These statements have been subjected to review by the Statutory Auditor of the Company. The reports of the Statutory Auditor are unqualified.

3 The Company has completed its IPO of Offer for Sale equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025.

On July 21, 2025, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, 4 comparative numbers for the quarter ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.

5 During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025.

6 The standalone financial information for the nine months ended December 31, 2024 has been extracted from the unaudited Financial Statements.

On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item 7 consistent with the guidance provided by the Institute of Chartered Accountants of India, in the standalone financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the new Labour Code and will take necessary steps to ensure compliance thereof and also provide appropriate accounting effects, as needed.

8 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of**

**Anthem Biosciences Limited**  
CIN:L24233KA2006PLC039703

*Ajay Bhardwaj*

**Ajay Bhardwaj**  
Managing Director  
DIN: 00333704

Place: Bangalore  
Date: February 05, 2026



**Independent Auditor's Review Report on the quarterly and year to date Unaudited Consolidated Financial Results of Anthem Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review report to  
The Board of Directors of  
Anthem Biosciences Limited  
Bangalore**

1. We have reviewed the Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the "Company") and its subsidiary (the Company and its subsidiary together referred to as "the Group"), included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter and nine months ended December 31, 2025, (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circulars issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended to the extent applicable.

The Statement includes the results of Neoanthem Lifesciences Private Limited (a wholly owned subsidiary).

4. The Statement includes the unaudited financial results of one subsidiary, Neoanthem Lifesciences Private Limited, whose financial statements reflect total revenue (before consolidation adjustments) of Rs. 299.15 million and total net loss (before consolidation adjustments) of Rs. 568.16 million and total comprehensive loss (net) of Rs. 569.33 million for the quarter ended on that date, as considered in the Statement, which have been reviewed by us.

Our opinion on the Statement is not modified in respect of the above matters.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For K. P. Rao & Co.,**  
Chartered Accountants  
FRN: 003135S

**Raghothama  
Mohan Lavi**  
Digitally signed by  
Raghothama Mohan Lavi  
Date: 2026.02.05 13:00:02  
+05'30'

**Mohan R Lavi**  
Partner  
Membership No. 029340

**Place: Bangalore**  
**Date: 5<sup>th</sup> February 2026**

**UDIN: 26029340WQYDTO5220**

**ANTHEM BIOSCIENCES LIMITED**  
**CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703**  
 REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099.  
 KARNATAKA INDIA.

Email : investors.abi@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND PERIOD ENDED DECEMBER 31, 2025**

Particulars	Quarter ended		Year to date		Rs in Mn Year End 31/03/2025
	31/12/2025	30/09/2025	31/12/2024	31/12/2025	
	Unaudited	Unaudited	Unaudited (Note 4)	Unaudited	Unaudited (Note 6)
<b>Income:</b>					
Revenue from operations	4,231.53	5,500.27	4,978.06	15,133.89	13,613.56
Other income	335.30	482.29	243.70	1,045.71	716.70
<b>Total income</b>	<b>4,566.83</b>	<b>5,982.56</b>	<b>5,221.77</b>	<b>16,179.60</b>	<b>14,330.26</b>
<b>Expenses:</b>					
Cost of materials consumed	1,849.22	2,012.63	2,551.27	5,483.90	6,470.53
Changes in inventories of finished goods, work-in-progress and stock in trade	(423.33)	220.98	(224.21)	484.37	(799.87)
Employee benefit expenses	704.79	677.16	568.71	2,102.28	2,007.16
Finance cost	3.52	30.31	25.52	49.94	98.08
Depreciation and amortisation expense	345.33	334.99	202.79	944.79	589.49
Other expenses	528.85	410.47	487.20	1,397.39	1,179.31
<b>Total expenses</b>	<b>3,008.39</b>	<b>3,686.53</b>	<b>3,611.29</b>	<b>10,462.66</b>	<b>9,544.70</b>
<b>Profit before exceptional items and tax</b>	<b>1,558.44</b>	<b>2,296.03</b>	<b>1,610.48</b>	<b>5,716.94</b>	<b>4,785.56</b>
Exceptional items (Note 8)	253.71	-	-	253.71	-
<b>Profit before tax</b>	<b>1,304.74</b>	<b>2,296.03</b>	<b>1,610.48</b>	<b>5,463.23</b>	<b>4,785.56</b>
<b>Tax expense</b>					
Current tax	377.80	637.51	377.21	1,515.99	1,204.43
Deferred tax	(1.23)	(75.77)	(10.04)	(73.10)	(105.24)
<b>Total tax expenses</b>	<b>376.57</b>	<b>561.74</b>	<b>367.17</b>	<b>1,442.89</b>	<b>1,099.19</b>
<b>Profit for the Period/Year</b>	<b>928.17</b>	<b>1,734.28</b>	<b>1,243.31</b>	<b>4,020.34</b>	<b>3,686.37</b>
<b>Other comprehensive income</b>					
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	(10.64)	(20.28)	(2.51)	(10.53)	(7.36)
Income tax on above	2.85	4.82	0.63	2.54	1.85
<b>Other comprehensive income/(loss) for the period/year</b>	<b>(7.80)</b>	<b>(15.46)</b>	<b>(1.88)</b>	<b>(7.99)</b>	<b>(5.50)</b>
<b>Total comprehensive income for the period/year</b>	<b>920.37</b>	<b>1,718.82</b>	<b>1,241.43</b>	<b>4,012.35</b>	<b>3,680.87</b>
<b>Paid-up equity share capital (face value of Rs.2 each)</b>	<b>1,123.22</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,123.22</b>	<b>1,118.15</b>
<b>Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'</b>					<b>22,980.48</b>
Non-controlling interests					
<b>Earnings per share (not annualised for the Quarter)</b>					
Basic	1.65	3.09	2.22	7.17	6.59
Diluted	1.64	3.06	2.21	7.09	6.56
					8.04

See accompanying notes to financial results



#### Notes to Consolidated Financial Statements

These unaudited consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

The above statement of unaudited consolidated financial results ("the Statements") of the Company for the quarter ended and period year ended 31st December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 5th February 2026. These statements have been subjected to review by the Statutory Auditor of the Company. The reports of the Statutory Auditor are unqualified.

<sup>3</sup> The Company has completed its IPO of Offer for Sale of equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025.

<sup>4</sup> On July 21, 2025 the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, comparative numbers for the quarter ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.

<sup>5</sup> During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025

<sup>6</sup> The consolidated financial information for the nine months ended December 31, 2024 has been extracted from the unaudited Financial Statements.

<sup>7</sup> The consolidated financial statements include the financial results of Anthem Biosciences Limited (Parent Company) and of the following subsidiaries: Neoanthem Lifesciences Private limited (wholly owned subsidiary)

<sup>8</sup> On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the consolidated financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the new Labour Code and will take necessary steps to ensure compliance thereof and also provide appropriate accounting effects, as needed.

<sup>9</sup> Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of**

**Anthem Biosciences Limited**  
CIN:L24233KA2006PLC039703



**Ajay Bhardwaj**  
Managing Director  
DIN: 00333704

Place: Bangalore  
Date: February 05, 2026



**Anthem Biosciences Limited**

**CONSOLIDATED SEGMENT INFORMATION**

**Amount (INR Mn)**

Sl.No	Particulars	Quarter Ended			Year to date		Year Ended	
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025	
		[Unaudited]	[Unaudited]	[Unaudited] (Note 4)	[Unaudited]	[Unaudited] (Note 6)	[Audited]	
<b>I Segment wise revenue and results:</b>								
<b>Segment revenue:</b>								
a)CRDMO		3,332.39	4,718.89	4,135.21	12,599.32	11,138.12	15,060.93	
	b)Speciality Ingredients	899.14	781.38	842.85	2,534.57	2,475.44	3,384.60	
	<b>Total</b>	<b>4,231.53</b>	<b>5,500.27</b>	<b>4,978.06</b>	<b>15,133.89</b>	<b>13,613.56</b>	<b>18,445.53</b>	
<b>II Segmental Results:</b>								
Gross profits from each segment								
a)CRDMO		2,347.93	2,885.21	2,219.61	7,891.55	6,694.38	9,303.31	
	b)Speciality Ingredients	457.70	381.45	431.38	1,274.07	1,248.52	1,703.10	
	<b>Total</b>	<b>2,805.63</b>	<b>3,266.67</b>	<b>2,650.99</b>	<b>9,165.62</b>	<b>7,942.90</b>	<b>11,006.40</b>	
Less: Selling and un-allocable expenditure net of other income								
		1,500.89	970.64	1,040.52	3,702.39	3,157.34	4,437.73	
<b>Total profit before tax:</b>								
		<b>1,304.74</b>	<b>2,296.02</b>	<b>1,610.47</b>	<b>5,463.23</b>	<b>4,785.56</b>	<b>6,568.68</b>	

